The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Morphologic features were examined to identify markers of inflammation, and proliferation index was assessed using Ki67 immunostaining.
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Frameworks used to make prescribing decisions on checkpoint inhibitors may need to be refined for adjuvant trials.
Additional research is needed on the best dose schedule for the drug.
Secondary end points were not significantly different between the 2 groups, including overall survival.
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Chimeric antigen receptor T-cell therapy “liso-cel” was deemed safe and clinically active in chronic lymphocytic leukemia and small lymphocytic leukemia.
Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.